8-K filing — Inhibrx Biosciences, Inc. (INBX)
Filed: 2026-09-28 AccNo: 0002007919-26-000050 Size: 7 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates
Inhibrx Biosciences reports Phase 2 HexAgon trial data showing improved response rates for INBRX-106 in head and neck cancer.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Novo Nordisk and Eli Lilly Just Got Some Fantastic News
A NIH-funded study found that the GLP-1 drug semaglutide extended lifespan and slowed aging in older mice by improving muscle and cognitive function and reducing inflammation. The findings could accelerate adoption of GLP-1 drugs from Novo Nordisk and Eli Lilly, with forecasts predicting 25 million Americans on these treatments by 2030 and a market reaching $190 billion by 2035.
9 Of 11 Sectors Rise In Friday Trading As Cyclicals Lead
Nine of 11 sectors are higher in Friday’s regular session, with cyclical sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap clearly standing apart from the other breaks across the table.
Eli Lilly's Biggest Shareholder Is Selling $347 Million of Stock. Should You Sell Too?
The Lilly Foundation, Eli Lilly's largest shareholder with 9.6% ownership, is selling 300,000 shares worth $347 million. However, this sale is a required annual charity payout and does not reflect bearish sentiment on the stock. Eli Lilly is leading the GLP-1 drug revolution with its tirzepatide drug (Mounjaro/Zepbound) becoming the world's best-selling drug. With Morgan Stanley forecasting the GLP-1 market to reach $190 billion by 2035 and Wall Street analysts targeting 10% upside, the article recommends buying rather than selling.
Meet the New Nasdaq-100 Stock That’s Crushing Nvidia, Micron, and Sandisk. Is It Too Late to Buy?
Moderna stock has surged over 600% in 2026, outperforming major AI stocks like Nvidia, Micron, and Sandisk, driven by progress in its oncology pipeline, particularly its personalized cancer vaccine candidate intismeran autogene. The stock now trades 61% above Wall Street's average price target of $122, and while the company shows promise as it transforms from a coronavirus vaccine company into a broader biotech player, the analyst recommends waiting for a pullback before buying.